AHL
LUCD icon

Abel Hall LLC’s Lucid Diagnostics LUCD Stock Holding History

Abel Hall LLC’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.6K Sell
25,728
-4,893
-16% -$6.23K 0.01% 777
2025
Q4 		$33.4K Buy
+30,621
New +$34.2K 0.01% 677

Other funds holding LUCD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Abel Hall LLC's LUCD Position: Q1 2026 in Review

Abel Hall LLC reduced its Lucid Diagnostics (LUCD) stake by 16% in Q1 2026, selling an estimated $6.23K and leaving 25,728 shares worth $29.6K. The position accounts for 0.01% of the portfolio, ranked #777.

Abel Hall LLC first reported a position in LUCD in Q4 2025 and has held it in 2 quarters since. The position peaked at $33.4K in Q4 2025. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • Abel Hall LLC held 25,728 shares of Lucid Diagnostics worth $29.6K as of Q1 2026.
  • Abel Hall LLC sold 4,893 Lucid Diagnostics shares in Q1 2026, an estimated $6.23K.
  • Lucid Diagnostics made up 0.01% of Abel Hall LLC's portfolio in Q1 2026, its #777 holding.
  • Abel Hall LLC first reported a position in Lucid Diagnostics in Q4 2025 and has held it in 2 quarters since.
  • Abel Hall LLC's Lucid Diagnostics position peaked at $33.4K in Q4 2025.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Abel Hall LLC's 13F filing for Q1 2026, filed 28 Apr 2026.